Consensus Repligen Corporation

Stocks

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 10:37:07 2026-10-06 EDT			5-day change	1st Jan Change
180.60 ^USD	-4.70%		-6.76%	+10.72%

10:29am	Repligen Closes BioLife Solutions Acquisition	MT
10-05	Freshworks to Join S&P SmallCap 600	MT

Evolution of the Average Target: Repligen Corporation

Evolution of the Target Price: Repligen Corporation

Changes in Analyst Recommendations: Repligen Corporation

ddfa9971963.Sm6XTmV6xxITpp4ZtNYVru3qMwJBpmzTzRF3Jkit1J8.Azv_ODcTtSsm38F82INz5aGlWnQG9RyBmyQEUC_ItsktKPZ5Cj6KS2mR0w~5e39be2261dcaf30274b0ef2efab00ce

Analysts' recommendations: Repligen Corporation

09-09	UBS Adjusts Price Target on Repligen to $225 From $195, Keeps Buy Rating	MT
09-01	Analyst recommendations: Duolingo, Robinhood, Adobe, CrowdStrike, Salesforce…
07-29	Repligen's Diversity of Growth Drivers Support Return to Mid-Teens Organic Sales Growth, RBC Says	MT
07-29	RBC Raises Price Target on Repligen to $185 From $160, Keeps Outperform Rating	MT
07-29	Deutsche Bank Adjusts Repligen Price Target to $200 From $180, Maintains Buy Rating	MT
07-07	Benchmark Upgrades Repligen to Buy From Hold, Price Target is $185	MT
05-15	Repligen Likely to Benefit From Diverse Growth Factors, RBC Says	MT
04-17	Rothschild & Co Redburn Initiates Repligen at Buy With $160 Price Target	MT
02-25	UBS Adjusts Price Target on Repligen to $195 From $200, Maintains Buy Rating	MT
01-16	UBS Adjusts Price Target on Repligen to $200 From $190, Maintains Buy Rating	MT
25-10-01	HSBC Initiates Repligen at Buy With $150 Price Target	MT
25-09-22	Repligen Shares Rise After Upgrade From Evercore ISI	MT
25-09-22	Evercore ISI Upgrades Repligen to Outperform From In Line, Price Target is $155	MT
25-09-03	RBC Lifts Price Target on Repligen to $205 From $204, Keeps Outperform Rating	MT
25-07-30	RBC Raises Price Target on Repligen to $204 From $193, Keeps Outperform Rating	MT
25-07-29	Life sciences firm Repligen beats Q2 revenue estimates, raises full-year guidance	RE
25-07-01	RBC Lifts Price Target on Repligen to $193 From $191, Keeps Outperform Rating	MT
25-06-24	Barclays Initiates Repligen at Overweight With $150 Price Target	MT
25-04-30	RBC Lowers Price Target on Repligen to $189 From $202, Keeps Outperform Rating	MT
25-04-29	Wolfe Research Upgrades Repligen to Outperform From Peerperform	MT
25-04-08	RBC Cuts Price Target on Repligen to $202 From $219, Keeps Outperform Rating	MT
25-03-18	Evercore ISI Initiates Repligen at In Line With $155 Price Target	MT
25-02-21	RBC Raises Price Target on Repligen to $205 From $203, Keeps Outperform Rating	MT
25-02-21	Deutsche Bank Adjusts Repligen Price Target to $195 From $190, Maintains Buy Rating	MT
25-02-10	TD Cowen Initiates Repligen at Buy With $200 Price Target	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REPLIGEN CORPORATION					+0.11%
	ABBOTT LABORATORIES					+20.62%
	MEDTRONIC PLC					+19.17%
	STRYKER CORPORATION					+28.67%
	ESSILORLUXOTTICA					+57.3%
	CENCORA, INC.					+17.25%
	HOYA CORPORATION					+23.27%
	BECTON, DICKINSON AND COMPANY					+8.76%
	IDEXX LABORATORIES, INC.					+33.06%
	DEXCOM, INC.					+9.87%
	Average					+21.81%
	Weighted average by Cap.					+24.46%